No Evidence That Analgesic Use after COVID-19 Vaccination Negatively Impacts Antibody Responses
Affiliation
BIO5 Institute, University of ArizonaDepartment of Pharmacy Practice and Science, R. Ken Coit College of Pharmacy, University of Arizona
Health Sciences, University of Arizona
Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ
University of Arizona Center on Aging, University of Arizona College of Medicine, Tucson, AZ
University of Arizona Genomics Core and the Arizona Research Labs, University of Arizona Genetics Core
Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ, United States
Department of Surgery, University of Arizona College of Medicine
Issue Date
2023-12-12
Metadata
Show full item recordPublisher
American Association of ImmunologistsCitation
Bonnie J. Lafleur, Lisa White, Michael D. Dake, Janko Z. Nikolich, Ryan Sprissler, Deepta Bhattacharya; No Evidence That Analgesic Use after COVID-19 Vaccination Negatively Impacts Antibody Responses. Immunohorizons 1 December 2023; 7 (12): 834–841. https://doi.org/10.4049/immunohorizons.2300090Journal
ImmunoHorizonsRights
© 2023 The Authors. This article is distributed under the terms of the CC BY 4.0 Unported license.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Uptake of mRNA vaccines, especially booster immunizations, against COVID-19 has been lower than hoped, perhaps in part due to their reactogenicity. Analgesics might alleviate symptoms associated with vaccination, but they might also impact immune responses. We semiquantitatively measured Ab responses following COVID-19 vaccination in 2354 human participants surveyed about analgesic use after vaccination. Participants who used nonsteroidal anti-inflammatory drugs or acetaminophen after vaccination showed elevated Ab levels against the receptor-binding domain of Spike protein relative to those who did not use analgesics. This pattern was observed for both mRNA-1273 and BNT162b2 and across age groups. Participants who used analgesics more frequently reported fatigue, muscle aches, and headaches than did those who did not use painkillers. Among participants who reported these symptoms, we observed no statistically significant differences in Ab levels irrespective of analgesic use. These data suggest that elevated Ab levels are associated with symptoms and inflammatory processes rather than painkiller use per se. Taken together, we find no evidence that analgesic use reduces Ab responses after COVID-19 vaccination. Recommendation of their use to alleviate symptoms might improve uptake of booster immunizations. Copyright © 2023 The Authors.Note
Open access journalISSN
2573-7732PubMed ID
38085168Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.4049/immunohorizons.2300090
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2023 The Authors. This article is distributed under the terms of the CC BY 4.0 Unported license.
Related articles
- Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
- Authors: Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö
- Issue date: 2022 Apr
- Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
- Authors: Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, Yagi Y, Kurosawa T, Greener B, Zhang Y, Walson JL
- Issue date: 2024 Apr
- Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
- Authors: Assantachai P, Niyomnaitham S, Toh ZQ, Thammasalee M, Pengsorn N, Monklang W, Licciardi PV, Chokephaibulkit K
- Issue date: 2023
- Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
- Authors: Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN, COV-BOOST study group
- Issue date: 2022 Aug
- Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
- Authors: Ventura-Enríquez Y, Cortina-De la Rosa E, Díaz-Padilla E, Murrieta S, Segundo-Martínez S, Fernández-Sánchez V, Vargas-De-León C
- Issue date: 2024 Apr 1